⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154814 | 0.95 | PKM (0.31) | — | |
| SCHEMBL151704 | 0.92 | — | — | |
| Methane SCHEMBL15974539 | 0.92 | PKM (0.30) | — | |
| SCHEMBL157035 | 0.90 | — | — | |
| SCHEMBL155349 | 0.89 | — | — | |
| SCHEMBL6364065 | 0.89 | — | — | |
| SCHEMBL8646647 | 0.89 | — | — | |
| SCHEMBL155700 | 0.83 | — | — | |
| SCHEMBL1440933 | 0.83 | — | — | |
| SCHEMBL2288427 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006256-B2 | Antitumor agent for thyroid cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8962655-B2 | Composition for treatment of undifferentiated gastric cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8952035-B2 | Combination of anti-angiogenic substance and anti-tumor platinum complex | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8865737-B2 | Antitumor agent for undifferentiated gastric cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8815241-B2 | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20090247576-A1 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090209580-A1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-4616008-A | LIPID-SOLUBLE CEPHALOSPORINS AND CYCLODEXTRINS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0163433-A2 | Antibacterial solid composition for oral administation | Takeda Chemical Industries, Ltd. (JP) | 1985-12-04 | — | — | EP | disclosed |